Bexxar tositumomab radiolabeled anti-CD20 monoclonal antibody regulatory update

CRXA and partner GlaxoSmithKline plc (GSK; LSE:GSK, London, U.K.) received a complete review letter from the FDA requesting additional clinical and manufacturing information for Bexxar to treat

Read the full 276 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE